Статья
НОВАЯ ФИКСИРОВАННАЯ КОМБИНАЦИЯ ИНГИБИТОРА АНГИОТЕНЗИН-ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА ПЕРИНДОПРИЛА И ВЫСОКОСЕЛЕКТИВНОГО β-АДРЕНОБЛОКАТОРА БИСОПРОЛОЛА: ПЕРВАЯ СРЕДИ РАВНЫХ
В статье представлена обширная доказательная база антигипертензивной эффективности и безопасности периндоприла и бисопролола. Рассмотрены вопросы применения этих препаратов у пациентов с артериальной гипертонией, ишемической болезнью сердца и хронической сердечной недостаточностью согласно международным и отечественным клиническим рекомендациям. Особое внимание уделено влиянию периндоприла и бисопролола на прогноз — риск развития сердечно-сосудистых осложнений с точки зрения доказательной медицины. Приведены данные о новой уникальной фиксированной комбинации этих препаратов, рассмотрены ее преимущества и механизм комплементарного действия, представлены результаты рандомизированных, клинических исследований, указывающие на высокий потенциал такой схемы комбинированного лечения.
1. Gottwald-Hostalek U, Sun N, Barho C, Hildemann S. Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. Clin Pharmacol Drug Dev 2017; 6 (1): 9-18. DOI: 10.1002/cpdd.309.
2. WHO. A global brief on hypertension. 2013. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/
3. Чазова И. Е., Ратова Л. Г., Бойцов С. А., Небиеридзе Д. В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010; 3: 5-26.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357. DOI: 10.1093/eurheartj/eht151.
5. Леонова М. В., Штейнберг Л. Л., Белоусов Ю. Б. и др., и группа исследователей. Результаты фармакоэпидемиологического исследования артериальной Гипертонии Пифагор IV: приверженность врачей. Российский кардиологический журнал 2015; 1 (117): 59-66. DOI: 10.15829/1560-4071-2015-1-59-66.
6. Леонова М. В. Периндоприл аргинин: новая лекарственная форма хорошо известного ингибитора ангиотензин-превращающего фермента. Кардиология 2008; 48 (10): 65-70.
7. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 188798. DOI: 10.1056/NEJMoa0801369.
8. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033-41. DOI: 10.1016/S01406736(01)06178-5.
9. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906. DOI: 10.1016/S0140-6736(05)67185-1.
10. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829-40. DOI: 10.1016/S0140-6736(07)61303-8.
11. Остроумова О. Д., Дудаев В. А., Фомина В. М. Артериальная гипертония и ишемическая болезнь сердца: как правильно выбрать лекарственные препараты. Лечебное дело 2014; 4: 41-9.
12. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8. DOI: 10.1016/S01406736(03)14286-9.
13. Rodriguez-Granillo GA, Vos J, Bruining N, et al. Investigators of the EUROPA Study. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluationstudy). Am J Cardiol 2007; 100 (2): 159-63. DOI: 10.1016/j.amjcard.2007.02.073.
14. Bots M, Remme W, Luscher T, et al. ACE inhibition and endothelial function: The PERFECT study, sub study of the EUROPA trial: Main findings. J Hypertens. 2005; 23 (suppl 2): S21. Abstract 3B.4.
15. Daly CA, Fox KM, Remme WJ, et al. EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26 (14): 1369-78. DOI: 10.1093/eurheartj/ehi225.
16. Brugts JJ, de Maat MP, Boersma E, et al. EUROPA-PERGENE investigators. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2009; 23 (2): 171-81. DOI: 10.1007/s10557-008-6156-1.
17. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17 (1): 83-91.
18. Brugts JJ, Boersma E, Deckers JW, et al. Abstract 5066: The Treatment Effect of Perindopril is Consistent in All Patients with Vascular Disease or High Risk of Vascular Disease: A Combined Analysis of Three Perindopril Trials. Circulation 2008; 118: S_1138.
19. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659-66. DOI: 10.1001/archinte.166.6.659.
20. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Russ J Cardiol 2017; 1 (141): 7-81. DOI: 10.15829/1560-4071-2017-1-7-81.
21. Cleland JG, Tendera M, Adamus J, et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27 (19): 2338-45. DOI: 10.1093/eurheartj/ehl250.
22. Клиническая фармакология: Учеб./Под ред. В. Г. Кукеса. 3-е изд., перераб. и доп. М.: ГЭОТАР-Медиа. 2006. 944 с.: ил. с. 243-56. ISBN 5-9704-0287-7.
23. Wellstein A, Palm D, Belz G. Affinity and selectivity of the -adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 1985; 8: Suppl 2: 11: 36-40. DOI: 10.1097/00005344-198511001-00006.
24. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993; 94 (2): 181-7. DOI: 10.1016/0002-9343(93)90181-N.
25. Parrinello G, Paterna S, Torres D, et al. One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, doubleblind study. Clin Drug Investig 2009; 29 (9): 591-600. DOI: 10.2165/11315250000000000-00000.
26. Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007; 20 (3): 311-8. DOI: 10.1016/j.amjhyper.2006.09.006.
27. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27 (3): 461-7. DOI: 10.1097/HJH.0b013e3283220ea4.
28. Zhou WJ, Wang RY, Li Y, et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One 2013; 8 (9): e72102. DOI: 10.1371/journal.pone.0072102.
29. Rosendorff C, Lackland DT, Allison M, et al. American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 2015; 65 (6): 1372-407. DOI: 10.1161/HYP.0000000000000018.
30. Task Force Members, Montalescot G, Sechtem U, et al. ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, et al.; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949-3003. DOI: 10.1093/eurheartj/eht296.
31. Wagner G. Summary of short-and long-term studies with bisoprolol in coronary heart disease. J Cardiovasc Pharmacol 1985; 8 (Suppl.11): S160-6. DOI: 10.1097/00005344-198511001-00029.
32. Prager G, Wagner G. Wirkung von Bisoprolol bei koronarer Herzkrankheit. Einfluß auf Herz-Kreislauf-Parameter und ischämische ST-Streckensenkung: Untersuchungen zur Wirkungsdauer. Dtsch Med Wschr (DMW) 1984; 109: 1914-7.
33. Prager G, Bethge H, Wagner G. Therapeutischer Dosisbereich von Bisoprolol während Langzeittherapie bei Angina-pectoris-Patienten. Herz/Kreisl 1988; 12: 505-10.
34. de Muinck ED, Buchner-Moell D, van de Ven LLM, Lie KI, on behalf of the MIRSA Study Group. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Oectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19: 870-5. DOI: 10.1097/00005344-199206000-00005.
35. Portegies MCM, Brouwer J, Ven LLMVD, et al. Effects of bisoprolol and isosorbide dinitrate on the circadian distribution of myocardial ischemia. Current therapeutic research-Clinical and experimental 1995; 56 (12): 1225-36. DOI: 10.1016/0011-393X(95)85066-X.
36. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. JACC 1995; 25 (1): 231-8. DOI: 10.1016/07351097(94)00345-Q.
37. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341 (24): 1789-94. DOI: 10.1056/NEJM199912093412402.
38. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90 (4): 1765-73. DOI: 10.1161/01.CIR.90.4.1765.
39. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9-13. DOI: 10.1016/S01406736(98)11181-9.
40. Willenheimer R, van Veldhuisen DJ, Silke B, et al. CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112 (16): 2426-35. DOI: 10.1161/CIRCULATIONAHA.105.582320.
41. Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and -blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015; 170 (6): 1092-8. DOI: 10.1016/j.ahj.2015.08.018.
42. Brugts JJ, Bertrand M, Remme W, et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Cardiovasc Drugs Ther 2017; 31 (4): 391-400. DOI: 10.1007/s10557-017-6747-9.
43. Madej A, Buldak L, Basiak M, et al. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther 2009; 47 (11): 686-94. DOI: 10.5414/CPP47686.